CA2487060A1 - Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency - Google Patents

Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency Download PDF

Info

Publication number
CA2487060A1
CA2487060A1 CA002487060A CA2487060A CA2487060A1 CA 2487060 A1 CA2487060 A1 CA 2487060A1 CA 002487060 A CA002487060 A CA 002487060A CA 2487060 A CA2487060 A CA 2487060A CA 2487060 A1 CA2487060 A1 CA 2487060A1
Authority
CA
Canada
Prior art keywords
seq
antibody
cdr
humanized
kappa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002487060A
Other languages
French (fr)
Other versions
CA2487060C (en
Inventor
Britta Hardy
Steven Tarran Jones
Leah Klapper
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mor Research Applications Ltd
Cure Tech Ltd
Original Assignee
Cure Tech Ltd.
Britta Hardy
Steven Tarran Jones
Leah Klapper
Mor-Research Applications Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cure Tech Ltd., Britta Hardy, Steven Tarran Jones, Leah Klapper, Mor-Research Applications Ltd. filed Critical Cure Tech Ltd.
Publication of CA2487060A1 publication Critical patent/CA2487060A1/en
Application granted granted Critical
Publication of CA2487060C publication Critical patent/CA2487060C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Abstract

The present invention provides to a humanized monoclonal antibody having immunostimulatory effects. This antibody binds specifically to B lymphoblastoid cells, induces proliferation and activation of peripheral blo od lymphocytes, and is capable of eliciting an anti-tumor effect upon administration to subjects suffering from cancer.

Claims (51)

1. An humanized monoclonal antibody having at least one complementarity determining region (CDR) of murine monoclonal antibody BAT-1 (mBAT-1) and a framework region (FR) derived from an acceptor human immunoglobulin wherein the humanized antibody retains the anti-tumor activity of mBAT-1 monoclonal antibody and is less immunogenic in a human subject than said marine antibody.
2. The humanized monoclonal antibody of claim 1 wherein the humanized antibody induces a greater anti-tumor effect than that induced by the parent marine BAT-1 antibody.
3. The humanized antibody of claim 1 comprising the complementarity-determining regions (CDRs) of murine monoclonal antibody BAT-1 (mBAT-1), wherein said humanized antibody comprises:
a. light chain variable regions of the formula:

wherein each FR is independently a framework region of a human antibody, and each CDR is a complementarity determining region, derived from mBAT-1;
b. the heavy chain variable regions of the formula:

wherein each FR is separately a framework region of a human antibody, and each CDR is a complementarity determining region, form mBAT-1.
4. A monoclonal antibody having a genetically modified Fab region comprising the complementarity-determining regions (CDRs) of marine monoclonal antibody BAT-1 (mBAT-1), wherein the genetically modified antibody retains the biological activity of said mBAT-1 and wherein said genetically modified monoclonal antibody comprises an amino acid sequence selected from:
(i) a heavy chain variable region comprising the amino acid sequences of: CDR
H1 (SEQ
ID NO:12); CDR H2 (SEQ ID NO:13); CDR H3 (SEQ ID NO:14); and a light chain variable region comprising the amino acid sequences of: CDR L1 (SEQ ID NO:9);
CDR L2 (SEQ ID NO:10); CDR L3 (SEQ ID NO:11);
(ii) heavy chain and light chain variable regions comprising the amino acid sequences having greater than about 80 percent similarity to all or part of the sequences of:
CDR H1 (SEQ ID NO:12); CDR H2 (SEQ ID NO:13); CDR H3 (SEQ ID NO:14); CDR L1 (SEQ ID NO:9); CDR (SEQ ID NO:10); CDR L3 (SEQ ID NO:11);

(iii) an antibody of (i) or (ii) in which one or more amino acid residues have been added, deleted, replaced or chemically modified without substantially affecting the biological activity or binding specificity of the antibody.
5. The monoclonal antibody of Claim 4, wherein the framework regions (FRs) are derived from a human antibody.
6. The humanized monoclonal antibody of claim 3 comprising complementarity-determining regions (CDRs) of murine monoclonal antibody BAT-1 (mBAT-1), wherein said humanized antibody comprises:
a. light chain variable regions of the formula:

wherein each FR is independently a framework region of a human antibody, and each CDR is a complementarity determining region, wherein the amino acid sequence of DR L1 is SARSSVSYMH (SEQ. ID NO. 9); CDR L2 is RTSNLAS (SEQ. ID NO. 10);
CDRL3 is QQRSSFPLT (SEQ. ID NO. 11);
b. the heavy chain variable regions of the formula:
FR H1-CDR H1- FR H2-CDR H2- FR H3-CDR H3- FR H4.
wherein each FR is separately a framework region of a human antibody, and each CDR is a complementarity determining region, wherein the amino acid sequence of CDR H1 is NYGMN (SEQ. ID NO. 12); CDR H2 is WINTDSGESTYAEEFKG (SEQ.
ID NO. 13); CDR H3 is VGYDALDY (SEQ. ID NO. 14).
7. The humanized antibody of Claim 6, wherein said humanized antibody induces a greater antitumor effect than murine BAT-1 monoclonal antibody.
8. The humanized antibody of Claim 6, wherein said humanized antibody induces a greater anti-metastatic effect than murine BAT-1 monoclonal antibody.
9. The humanized antibody of claim 6, wherein the antibody is a full length antibody.
10. The humanized antibody of Claim 9, wherein the antibody is of isotype IgG.
11. The humanized antibody of Claim 10, wherein said isotype subclass is selected from IgG1 or IgG4.
12. The humanized antibody of Claim 6, wherein the FR of the heavy chain variable region are derived from the FRs of the heavy chain variable region of the human hsighv1295 antibody.
13. The humanized antibody of Claim 6, wherein the FRs of the kappa light chain variable region are based on the FRs of the kappa light chain variable region of the human TEL9 antibody.
14. The humanized antibody of claim 6, having a human kappa constant region.
15. An antibody fragment derived from humanized antibody of claim 6, wherein the antibody fragment is selected from the group consisting of Fv, F(ab'), F(ab')a, a single chain antibody.
16. The humanized antibody of claim 6, wherein the antibody is further labeled with a detectable label, immobilized on a solid phase, or conjugated to a heterologous compound.
17. The humanized antibody of claim 6, wherein said humanized monoclonal antibody light chain variable regions are selected from the group consisting of: BATR.kappa.A
(SEQ ID NO.
15), BATR.kappa.B (SEQ. ID NO. 16), BATR.kappa.C (SEQ. ID NO. 17), BATR.kappa.D (SEQ. ID NO.
18), and the heavy chain variable regions are selected from the group consisting of BATRH A (SEQ. ID NO. 20), BATRH B (SEQ. ID NO. 21), BATRH C (SEQ. ID NO. 22), BATRH D (SEQ. ID NO. 23) or BATRH E (SEQ. ID NO. 24).
18. The humanized antibody of claim 6, wherein said humanized monoclonal antibody variable regions are selected from the group consisting of BATRH
A/BATR.kappa.A (SEQ. ID
NO. 20/SEQ. ID NO. 15), BATRH B/BATR.kappa.A (SEQ. ID NO. 21/SEQ. ID NO. 15), BATRH B/BATR.kappa.B (SEQ. ID NO. 21/SEQ. ID NO. 16), BATRH C/BATR.kappa.B
(SEQ. ID NO.
22/SEQ. ID NO. 16), BATRH B/BATR.kappa.D (SEQ. ID NO. 21/SEQ. ID NO. 18), or BATRH C/BATR.kappa.D (SEQ. ID NO. 22/SEQ. ID NO. 18).
19. The antibody of Claim 6 generated by recombinant DNA technology, utilizing CDR
grafting.
20. An isolated polynucleotide construct encoding any of the monoclonal antibodies of Claims 1-19 or fragments thereof.
21. The isolated polynucleotide construct according to Claim 20 encoding a kappa light chain variable region selected from the group consisting of SEQ ID NO. 15, SEQ ID
NO. 16, SEQ ID NO. 17, SEQ ID NO. 18.
22. The isolated polynucleotide construct according to Claim 21 selected from the group consisting of: SEQ ID NO. 87, SEQ ID NO. 88, SEQ ID NO. 89.
23. The isolated polynucleotide construct according to Claim 20 encoding a heavy chain variable region selected from the group consisting of SEQ ID NO. 20, SEQ ID
NO. 21, SEQ ID NO. 22, SEQ ID NO. 23, SEQ ID NO. 24.
24. The isolated polynucleotide construct according to Claim 23 selected from the group consisting of SEQ ID NO. 90, SEQ ID NO. 91, SEQ ID NO: 92.
25. A vector comprising any of the polynucleotides of Claim 20 to 24.
26. The vector of Claim 25, further comprising at least one polynucleotide sequence encoding a component selected from the group consisting of a promoter operatively linked to the polynucleotide encoding the antibody, one or more resistance gene, a Kozak sequence, an origin of replication, one or more selection marker genes, an enhancer element, transcription terminator, a signal peptide, genomic human kappa constant region, genomic human IgG constant region.
27. The vector of Claim 26, wherein the vector is a plasmid or a virus.
28. The vector of Claim 27, selected from the group comprising: pKN110, pG1D200, pG1KD210, pUC or pBR322.
29. The vector of Claim 25, comprising the polynucleotide sequence of SEQ ID
NO. 93.
30. A host cell comprising the vector of any of Claims 23-27.
31. The host cell of Claim 30, capable of expressing an antibody or fragments thereof.
32. The host cell Claim 30, wherein the cell is selected from eukaryotic and prokaryotic.
33. The host cell of Claim 30, selected from the group consisting of: CHO, CHOdhfr, NSO, COS or COS7 cells.
34. A pharmaceutical composition comprising as an active ingredient the antibody or antibody fragments of any of Claims 1-19.
35. The pharmaceutical composition of Claim 34, further comprising a physiologically acceptable carrier, diluent, or stabilizer.
36. A method for treating a subject in need thereof, comprising the step of treating said subject with a therapeutically effective amount of a pharmaceutical composition containing as an active ingredient the antibody or antibody fragments of any of Claims 1-19.
37. The method for treating a subject of Claim 36 further comprising treatment in conjunction with additional therapeutic agents selected from, cytokines, IL-1 (interleuken-1), IL-2, IL-6, IFN-.alpha. (interferon-.alpha.), cell vaccines, antibodies, T-cell stimulatory antibody, and anti-tumor therapeutic antibody.
38. The method for treating a subject of Claim 37 wherein the treatments are administered substantially at the same time.
39. The method of Claim 37 wherein the treatments are co-administered in a single composition.
40. The method of Claim 37 wherein the treatments are administered in separate compositions.
41. The method for treating a subject of Claim 37 wherein the treatments are administered sequentially.
42. The method of any of Claim 36, further comprising cell therapy.
43. The method for treating a subject of Claim 42 wherein the treatments are administered substantially at the same time.
44. The method of Claim 42 wherein the treatments are co-administered in a single composition.
45. The method of Claim 42 wherein the treatments are administered in separate compositions.
46. The method for treating a subject of Claim 47 wherein the treatments are administered sequentially.
47. The method of any one of Claims 42 through 46 wherein the cells are selected from autologous and allogeneic cells.
48. The method of any of Claim 36 through 47, wherein the treatments are independently selected from ex vivo and in vivo.
49. The method of any of Claim 36 through 47, for treating cancer.
50. The method of Claim 49, wherein the cancer is selected from melanoma, lung tumors, colorectal cancer or hepatic metastasis.
51. A method for producing the antibody of any of Claims 1-19, comprising:
(i) transfecting a host cell with a vector comprising a polynucleotide sequence encoding said antibody, or co-transfecting the host cell with 2 vectors each comprising a polynucleotide sequence encoding the heavy or light chain regions of said antibody;
(ii) culturing the host cell of (i) so that said antibody is expressed; and (iii) recovering the antibody from the host cells culture of (ii).
CA2487060A 2002-05-23 2003-05-22 Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency Expired - Fee Related CA2487060C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL149820 2002-05-23
IL14982002A IL149820A0 (en) 2002-05-23 2002-05-23 Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
PCT/IL2003/000425 WO2003099196A2 (en) 2002-05-23 2003-05-22 Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency

Publications (2)

Publication Number Publication Date
CA2487060A1 true CA2487060A1 (en) 2003-12-04
CA2487060C CA2487060C (en) 2011-01-04

Family

ID=28460428

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2487060A Expired - Fee Related CA2487060C (en) 2002-05-23 2003-05-22 Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency

Country Status (14)

Country Link
US (3) US7332582B2 (en)
EP (1) EP1575484B1 (en)
JP (2) JP4764627B2 (en)
KR (1) KR101169254B1 (en)
AU (1) AU2003230183B2 (en)
CA (1) CA2487060C (en)
CY (1) CY1117114T1 (en)
DK (1) DK1575484T3 (en)
ES (1) ES2549303T3 (en)
HU (1) HUE025710T2 (en)
IL (3) IL149820A0 (en)
PT (1) PT1575484E (en)
SI (1) SI1575484T1 (en)
WO (1) WO2003099196A2 (en)

Families Citing this family (239)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL129299A0 (en) 1999-03-31 2000-02-17 Mor Research Applic Ltd Monoclonal antibodies antigens and diagnosis of malignant diseases
WO2002051438A2 (en) 2000-12-22 2002-07-04 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Use of repulsive guidance molecule (rgm) and its modulators
JP4409430B2 (en) 2002-07-03 2010-02-03 小野薬品工業株式会社 Immunostimulatory composition
CN1753912B (en) * 2002-12-23 2011-11-02 惠氏公司 Antibodies against PD-1 and uses therefor
WO2006021955A2 (en) * 2004-08-23 2006-03-02 Mor Research Applications Ltd. Use of bat monoclonal antibody for immunotherapy
CN109485727A (en) 2005-05-09 2019-03-19 小野药品工业株式会社 The human monoclonal antibodies of programmed death-1 (PD-1) and the method for carrying out treating cancer using anti-PD-1 antibody
DK1907424T3 (en) 2005-07-01 2015-11-09 Squibb & Sons Llc HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED death ligand 1 (PD-L1)
CN101277974A (en) 2005-09-30 2008-10-01 阿伯特有限及两合公司 Binding domains of proteins of the repulsive guidance molecule (RGM) protein family and functional fragments thereof, and their use
WO2010123874A1 (en) 2009-04-20 2010-10-28 Oxford Biotherapeutics Ltd. Antibodies specific to cadherin-17
ES2437327T3 (en) 2007-06-18 2014-01-10 Merck Sharp & Dohme B.V. Antibodies for the human programmed PD-1 receptor of programmed death
US20110189206A1 (en) * 2008-01-03 2011-08-04 Barbas Iii Carlos F Antibody Targeting Through a Modular Recognition Domain
US8747847B2 (en) * 2008-02-11 2014-06-10 Curetech Ltd. Monoclonal antibodies for tumor treatment
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
UA112050C2 (en) * 2008-08-04 2016-07-25 БАЄР ХЕЛСКЕР ЛЛСі THERAPEUTIC COMPOSITION CONTAINING MONOCLONAL ANTIBODY AGAINST TISSUE FACTOR INHIBITOR (TFPI)
PE20110435A1 (en) 2008-08-25 2011-07-20 Amplimmune Inc ANTAGONIST COMPOSITIONS OF PD-1
MX2012006560A (en) 2009-12-08 2012-10-05 Abbott Gmbh & Co Kg Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration.
SI2542257T1 (en) 2010-03-01 2018-01-31 Bayer Healthcare Llc Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
RU2012153241A (en) * 2010-05-11 2014-06-20 Авео Фармасьютикалз, Инк. ANTIBODIES TO FGFR2
CN103534268B (en) * 2010-10-20 2016-05-18 牛津生物疗法有限公司 Antibody
HUE052198T2 (en) 2011-07-21 2021-04-28 Sumitomo Dainippon Pharma Oncology Inc Heterocyclic protein kinase inhibitors
US8686119B2 (en) 2011-07-24 2014-04-01 Curetech Ltd. Variants of humanized immunomodulatory monoclonal antibodies
RS57603B1 (en) 2012-01-27 2018-11-30 Abbvie Deutschland Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
WO2013155493A1 (en) 2012-04-12 2013-10-17 Yale University Methods of treating inflammatory and autoimmune diseases and disorders
JP6279466B2 (en) * 2012-04-27 2018-02-14 Ｊｃｒファーマ株式会社 New expression vector
CA2874979A1 (en) 2012-05-31 2014-04-24 Edwige Gros Antigen binding proteins that bind dll-4
CN112587658A (en) 2012-07-18 2021-04-02 博笛生物科技有限公司 Targeted immunotherapy for cancer
DK2888283T3 (en) 2012-08-24 2018-11-19 Univ California ANTIBODIES AND VACCINES FOR TREATING ROR1 CANCER AND INHIBITIVE METASTASE
WO2014122271A1 (en) 2013-02-07 2014-08-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the survival time of patients suffering from diffuse large b-cell lymphomas
EP3178849B1 (en) 2013-09-20 2019-03-20 Bristol-Myers Squibb Company Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors
EP3757130A1 (en) 2013-09-26 2020-12-30 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
RU2672055C2 (en) 2013-11-01 2018-11-09 Йейл Юниверсити Modular particles for immunotherapy
US9580504B1 (en) 2013-11-07 2017-02-28 Curetech Ltd. Pidilizumab monoclonal antibody therapy following stem cell transplantation
DE202014010499U1 (en) 2013-12-17 2015-10-20 Kymab Limited Targeting of human PCSK9 for cholesterol treatment
CA2936377A1 (en) 2014-01-10 2015-07-16 Shanghai Birdie Biotech, Inc. Compounds and compositions for treating egfr expressing tumors
JOP20200094A1 (en) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc Antibody molecules to pd-1 and uses thereof
JOP20200096A1 (en) 2014-01-31 2017-06-16 Children’S Medical Center Corp Antibody molecules to tim-3 and uses thereof
US9394365B1 (en) 2014-03-12 2016-07-19 Yeda Research And Development Co., Ltd Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease
US10618963B2 (en) 2014-03-12 2020-04-14 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
US10519237B2 (en) 2014-03-12 2019-12-31 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
NZ747418A (en) 2014-03-12 2023-05-26 Yeda Res & Dev Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns
EP3151921B1 (en) 2014-06-06 2019-08-28 Bristol-Myers Squibb Company Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
TWI693232B (en) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 Covalently bonded diabodies having immunoreactivity with pd-1 and lag-3, and methods of use thereof
CN105440135A (en) 2014-09-01 2016-03-30 博笛生物科技有限公司 Anti-PD-L1 conjugate for treating tumors
TWI727427B (en) 2014-07-09 2021-05-11 英屬開曼群島商博笛生物科技有限公司 Anti-pd-1 combinations for treating tumors
PL3186281T3 (en) 2014-08-28 2019-10-31 Halozyme Inc Combination therapy with a hyaluronan-degrading enzyme and an immune checkpoint inhibitor
EP3191097B1 (en) 2014-09-13 2019-10-23 Novartis AG Combination therapies
BR112017007765B1 (en) 2014-10-14 2023-10-03 Halozyme, Inc COMPOSITIONS OF ADENOSINE DEAMINASE-2 (ADA2), VARIANTS THEREOF AND METHODS OF USING THE SAME
HUE052526T2 (en) 2014-11-21 2021-05-28 Bristol Myers Squibb Co Antibodies comprising modified heavy constant regions
TWI758928B (en) 2014-11-21 2022-03-21 美商必治妥美雅史谷比公司 Antibodies against cd73 and uses thereof
CA2971732A1 (en) 2014-12-23 2016-06-30 Bristol-Myers Squibb Company Antibodies to tigit
US10983128B2 (en) 2015-02-05 2021-04-20 Bristol-Myers Squibb Company CXCL11 and SMICA as predictive biomarkers for efficacy of anti-CTLA4 immunotherapy
CN113603784A (en) 2015-05-29 2021-11-05 艾吉纳斯公司 anti-CTLA-4 antibodies and methods of use thereof
LT3303396T (en) 2015-05-29 2023-01-10 Bristol-Myers Squibb Company Antibodies against ox40 and uses thereof
CA2985818A1 (en) 2015-05-31 2016-12-08 Curegenix Corporation Combination compositions comprising an antagonist of porcupine and a pd-l/pd-1 axis antagonist for immunotherapy
TWI773646B (en) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 Lag-3-binding molecules and methods of use thereof
TW201709929A (en) 2015-06-12 2017-03-16 宏觀基因股份有限公司 Combination therapy for the treatment of cancer
MY193727A (en) 2015-06-24 2022-10-27 Janssen Biotech Inc Immune modulation and treatment of solid tumors with antibodies that specifically bind cd38
EA201890162A1 (en) 2015-06-29 2018-07-31 Бристол-Маерс Сквибб Компани ANTIBODIES TO CD40 WITH ENHANCED AGONISTIC ACTIVITY
KR20180040138A (en) 2015-07-13 2018-04-19 싸이톰스 테라퓨틱스, 인크. Anti-PD-1 antibodies, activatable anti-PD-1 antibodies, and methods of using them
MD3456346T2 (en) 2015-07-30 2021-11-30 Macrogenics Inc PD-1 and LAG-3 binding molecules and methods of use thereof
AU2016306597A1 (en) 2015-08-07 2018-02-22 Pieris Pharmaceuticals Gmbh Novel fusion polypeptide specific for LAG-3 and PD-1
BR112018003186A2 (en) 2015-09-01 2018-09-25 Agenus Inc. anti-pd-1 antibodies and their methods of use
AU2016332725A1 (en) 2015-09-29 2018-03-22 Celgene Corporation PD-1 binding proteins and methods of use thereof
BR112018006251A2 (en) 2015-09-30 2018-10-16 Janssen Biotech Inc antagonist antibodies that specifically bind to human cd40 and methods of use
RU2731202C2 (en) 2015-10-08 2020-08-31 Макродженикс, Инк. Combined therapy for cancer treatment
EP3371311B1 (en) 2015-11-06 2021-07-21 Orionis Biosciences BV Bi-functional chimeric proteins and uses thereof
AU2016356780A1 (en) 2015-11-19 2018-06-28 Bristol-Myers Squibb Company Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof
UA125611C2 (en) 2015-12-14 2022-05-04 Макродженікс, Інк. Bispecific molecules having immunoreactivity in relation to pd-1 and ctla-4, and methods of their use
CN106943596A (en) 2016-01-07 2017-07-14 博笛生物科技（北京）有限公司 Anti-CD 20 for treating tumour is combined
CN106943598A (en) 2016-01-07 2017-07-14 博笛生物科技（北京）有限公司 Anti- HER2 for treating tumour is combined
CN115252792A (en) 2016-01-07 2022-11-01 博笛生物科技有限公司 anti-EGFR combinations for the treatment of tumors
CA3013551A1 (en) 2016-02-05 2017-08-10 Orionis Biosciences Nv Clec9a binding agents and use thereof
SG11201805941WA (en) 2016-02-17 2018-09-27 Novartis Ag Tgfbeta 2 antibodies
US20190284293A1 (en) 2016-03-04 2019-09-19 Bristol-Myers Squibb Company Combination therapy with anti-cd73 antibodies
US20170252417A1 (en) 2016-03-07 2017-09-07 Massachusetts Institute Of Technology Protein-chaperoned t-cell vaccines
WO2017165778A1 (en) 2016-03-24 2017-09-28 Millennium Pharmaceuticals, Inc. Methods of treating gastrointestinal immune-related adverse events in immune oncology treatments
TW201735949A (en) 2016-03-24 2017-10-16 千禧製藥公司 Methods of treating gastrointestinal immune-related adverse events in anti-CTLA4 anti-PD-1 combination treatments
SG11201808821WA (en) 2016-04-18 2018-11-29 Celldex Therapeutics Inc Agonistic antibodies that bind human cd40 and uses thereof
CA3023881A1 (en) 2016-05-13 2017-11-16 Orionis Biosciences Nv Therapeutic targeting of non-cellular structures
WO2017194783A1 (en) 2016-05-13 2017-11-16 Orionis Biosciences Nv Targeted mutant interferon-beta and uses thereof
TWI781934B (en) 2016-05-27 2022-11-01 美商艾吉納斯公司 Anti-tim-3 antibodies and methods of use thereof
WO2017210335A1 (en) 2016-06-01 2017-12-07 Bristol-Myers Squibb Company Imaging methods using 18f-radiolabeled biologics
CN109715196A (en) 2016-06-13 2019-05-03 转矩医疗股份有限公司 For promoting the composition and method of immune cell function
US10688181B2 (en) 2016-06-27 2020-06-23 The Regents Of The University Of California Cancer treatment combinations
CN117683135A (en) 2016-07-14 2024-03-12 百时美施贵宝公司 Antibodies against TIM3 and uses thereof
WO2018053434A1 (en) 2016-09-16 2018-03-22 The Johns Hopkins University Protein nanocages with enhanced mucus penetration for targeted tissue and intracellular delivery
WO2018053405A1 (en) 2016-09-19 2018-03-22 Celgene Corporation Methods of treating immune disorders using pd-1 binding proteins
JP2019534859A (en) 2016-09-19 2019-12-05 セルジーン コーポレイション Method for treating vitiligo using PD-1 binding protein
RU2759334C2 (en) 2016-09-21 2021-11-12 Нексткьюр, Инк. Antibodies against siglec-15 and their application methods
TW202246349A (en) 2016-10-11 2022-12-01 美商艾吉納斯公司 Anti-lag-3 antibodies and methods of use thereof
WO2018077893A1 (en) 2016-10-24 2018-05-03 Orionis Biosciences Nv Targeted mutant interferon-gamma and uses thereof
SG11201903359RA (en) 2016-11-02 2019-05-30 Engmab Sarl Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma
WO2018094275A1 (en) 2016-11-18 2018-05-24 Tolero Pharmaceuticals, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
WO2018098352A2 (en) 2016-11-22 2018-05-31 Jun Oishi Targeting kras induced immune checkpoint expression
BR112019011582A2 (en) 2016-12-07 2019-10-22 Agenus Inc. antibodies and their methods of use
MD3551660T2 (en) 2016-12-07 2024-03-31 Agenus Inc Anti-CTLA-4 antibodies and methods of use thereof
JP2020503883A (en) 2017-01-13 2020-02-06 アジェナス インコーポレイテッド T-cell receptor binding to NY-ESO-1 and method of using same
WO2018134279A1 (en) 2017-01-18 2018-07-26 Pieris Pharmaceuticals Gmbh Novel fusion polypeptides specific for lag-3 and pd-1
WO2018134784A1 (en) 2017-01-20 2018-07-26 Novartis Ag Combination therapy for the treatment of cancer
JP2020505955A (en) 2017-02-06 2020-02-27 オリオンズ バイオサイエンス インコーポレイテッド Targeted modified interferon and uses thereof
AU2018216032B2 (en) 2017-02-06 2022-04-07 Orionis Biosciences BV Targeted chimeric proteins and uses thereof
WO2018146612A1 (en) 2017-02-10 2018-08-16 Novartis Ag 1-(4-amino-5-bromo-6-(1 h-pyrazol-1-yl)pyrimidin-2-yl)-1 h-pyrazol-4-ol and use thereof in the treatment of cancer
TW201841942A (en) 2017-04-13 2018-12-01 美商艾吉納斯公司 Anti-CD137 antibodies and methods of use thereof
CN108728444A (en) 2017-04-18 2018-11-02 长春华普生物技术股份有限公司 Immunoregulation polynucleotide and its application
WO2018200430A1 (en) 2017-04-26 2018-11-01 Bristol-Myers Squibb Company Methods of antibody production that minimize disulfide bond reduction
CN108794467A (en) 2017-04-27 2018-11-13 博笛生物科技有限公司 2- amino-quinoline derivatives
RS64576B1 (en) 2017-05-01 2023-10-31 Agenus Inc Anti-tigit antibodies and methods of use thereof
WO2018213297A1 (en) 2017-05-16 2018-11-22 Bristol-Myers Squibb Company Treatment of cancer with anti-gitr agonist antibodies
AR111760A1 (en) 2017-05-19 2019-08-14 Novartis Ag COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF SOLID TUMORS THROUGH INTRATUMORAL ADMINISTRATION
KR20200013241A (en) 2017-05-25 2020-02-06 브리스톨-마이어스 스큅 컴퍼니 Antibodies Containing Modified Heavy Chain Constant Regions
US11723975B2 (en) 2017-05-30 2023-08-15 Bristol-Myers Squibb Company Compositions comprising an anti-LAG-3 antibody or an anti-LAG-3 antibody and an anti-PD-1 or anti-PD-L1 antibody
CN110720039A (en) 2017-05-30 2020-01-21 百时美施贵宝公司 Treatment of LAG-3 positive tumors
EP3630842A2 (en) 2017-05-30 2020-04-08 Bristol-Myers Squibb Company Compositions comprising a combination of an anti-lag-3 antibody, a pd-1 pathway inhibitor, and an immunotherapeutic agent
JOP20190279A1 (en) 2017-05-31 2019-11-28 Novartis Ag Crystalline forms of 5-bromo-2,6-di(1 h-pyrazol-1-yl)pyrimidin-4-amine and new salts
WO2018229715A1 (en) 2017-06-16 2018-12-20 Novartis Ag Compositions comprising anti-cd32b antibodies and methods of use thereof
CN110785187B (en) 2017-06-22 2024-04-05 诺华股份有限公司 Antibody molecules against CD73 and uses thereof
US20200172628A1 (en) 2017-06-22 2020-06-04 Novartis Ag Antibody molecules to cd73 and uses thereof
AU2017419352A1 (en) 2017-06-23 2019-12-12 Birdie Biopharmaceuticals, Inc. Pharmaceutical compositions
US11560425B2 (en) 2017-06-27 2023-01-24 Neuracle Science Co., Ltd. Use of anti-FAM19A5 antibodies for treating cancers
JP2020525483A (en) 2017-06-27 2020-08-27 ノバルティス アーゲー Dosing regimens for anti-TIM-3 antibodies and uses thereof
AU2018302283A1 (en) 2017-07-20 2020-02-06 Novartis Ag Dosage regimens of anti-LAG-3 antibodies and uses thereof
SG11202001319QA (en) 2017-09-04 2020-03-30 Agenus Inc T cell receptors that bind to mixed lineage leukemia (mll)-specific phosphopeptides and methods of use thereof
KR20200045520A (en) 2017-09-07 2020-05-04 오거스타 유니버시티 리서치 인스티튜트, 인크. Antibodies to programmed cell death protein 1
US11497756B2 (en) 2017-09-12 2022-11-15 Sumitomo Pharma Oncology, Inc. Treatment regimen for cancers that are insensitive to BCL-2 inhibitors using the MCL-1 inhibitor alvocidib
WO2019075090A1 (en) 2017-10-10 2019-04-18 Tilos Therapeutics, Inc. Anti-lap antibodies and uses thereof
US20210040205A1 (en) 2017-10-25 2021-02-11 Novartis Ag Antibodies targeting cd32b and methods of use thereof
JP2021501801A (en) 2017-11-01 2021-01-21 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Immunostimulatory agonist antibody for use in the treatment of cancer
MX2020004756A (en) 2017-11-16 2020-08-20 Novartis Ag Combination therapies.
TW201925782A (en) 2017-11-30 2019-07-01 瑞士商諾華公司 BCMA-targeting chimeric antigen receptor, and uses thereof
US11946094B2 (en) 2017-12-10 2024-04-02 Augusta University Research Institute, Inc. Combination therapies and methods of use thereof
WO2019133747A1 (en) 2017-12-27 2019-07-04 Bristol-Myers Squibb Company Anti-cd40 antibodies and uses thereof
US11324774B2 (en) 2018-01-05 2022-05-10 Augusta University Research Institute, Inc. Compositions of oral alkaline salts and metabolic acid inducers and uses thereof
EP3737408A1 (en) 2018-01-08 2020-11-18 Novartis AG Immune-enhancing rnas for combination with chimeric antigen receptor therapy
KR20200108870A (en) 2018-01-12 2020-09-21 브리스톨-마이어스 스큅 컴퍼니 Antibodies to TIM3 and uses thereof
SG11202005323SA (en) 2018-01-12 2020-07-29 Bristol Myers Squibb Co Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer
WO2019144126A1 (en) 2018-01-22 2019-07-25 Pascal Biosciences Inc. Cannabinoids and derivatives for promoting immunogenicity of tumor and infected cells
KR20200112913A (en) 2018-01-23 2020-10-05 넥스트큐어 인코포레이티드 B7-H4 antibody and method of use
WO2019152660A1 (en) 2018-01-31 2019-08-08 Novartis Ag Combination therapy using a chimeric antigen receptor
CA3090406A1 (en) 2018-02-05 2019-08-08 Orionis Biosciences, Inc. Fibroblast binding agents and use thereof
WO2019157124A1 (en) 2018-02-08 2019-08-15 Bristol-Myers Squibb Company Combination of a tetanus toxoid, anti-ox40 antibody and/or anti-pd-1 antibody to treat tumors
WO2019160956A1 (en) 2018-02-13 2019-08-22 Novartis Ag Chimeric antigen receptor therapy in combination with il-15r and il15
US20210002373A1 (en) 2018-03-01 2021-01-07 Nextcure, Inc. KLRG1 Binding Compositions and Methods of Use Thereof
CA3092589A1 (en) 2018-03-21 2019-09-26 Five Prime Therapeutics, Inc. Antibodies binding to vista at acidic ph
CA3096674A1 (en) 2018-04-12 2019-10-17 Bristol-Myers Squibb Company Anticancer combination therapy with cd73 antagonist antibody and pd-1/pd-l1 axis antagonist antibody
US20210147547A1 (en) 2018-04-13 2021-05-20 Novartis Ag Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
CA3096909A1 (en) 2018-04-26 2019-10-31 Agenus Inc. Heat shock protein-binding peptide compositions and methods of use thereof
TW202015726A (en) 2018-05-30 2020-05-01 瑞士商諾華公司 Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
WO2019232244A2 (en) 2018-05-31 2019-12-05 Novartis Ag Antibody molecules to cd73 and uses thereof
EP3802611A2 (en) 2018-06-01 2021-04-14 Novartis AG Binding molecules against bcma and uses thereof
US20210221908A1 (en) 2018-06-03 2021-07-22 Lamkap Bio Beta Ltd. Bispecific antibodies against ceacam5 and cd47
JP7411627B2 (en) 2018-07-09 2024-01-11 ファイヴ プライム セラピューティクス インク Antibody that binds to ILT4
MX2021000213A (en) 2018-07-11 2021-03-25 Five Prime Therapeutics Inc Antibodies binding to vista at acidic ph.
KR20210030973A (en) 2018-07-11 2021-03-18 액팀 테라퓨틱스, 인코퍼레이티드 Engineered immunostimulatory bacterial strains and uses thereof
US20210277135A1 (en) 2018-07-13 2021-09-09 Bristol-Myers Squibb Company Ox-40 agonist, pd-1 pathway inhibitor and ctla-4 inhibitor combination for use in a method of treating a cancer or a solid tumor
BR112021000727A2 (en) 2018-07-20 2021-04-13 Surface Oncology, Inc. ANTI-CD112R COMPOSITIONS AND METHODS
WO2020021465A1 (en) 2018-07-25 2020-01-30 Advanced Accelerator Applications (Italy) S.R.L. Method of treatment of neuroendocrine tumors
SG11202100693UA (en) 2018-07-26 2021-02-25 Bristol Myers Squibb Co Lag-3 combination therapy for the treatment of cancer
WO2020021061A1 (en) 2018-07-26 2020-01-30 Pieris Pharmaceuticals Gmbh Humanized anti-pd-1 antibodies and uses thereof
CA3106881A1 (en) 2018-08-27 2020-03-05 Pieris Pharmaceuticals Gmbh Combination therapies comprising cd137/her2 bispecific agents and pd-1 axis inhibitors and uses thereof
WO2020044252A1 (en) 2018-08-31 2020-03-05 Novartis Ag Dosage regimes for anti-m-csf antibodies and uses thereof
US20210340279A1 (en) 2018-08-31 2021-11-04 Yale University Compositions and methods of using cell-penetrating antibodies in combination with immune checkpoint modulators
WO2020049534A1 (en) 2018-09-07 2020-03-12 Novartis Ag Sting agonist and combination therapy thereof for the treatment of cancer
CA3112578A1 (en) 2018-09-19 2020-03-26 Alpine Immune Sciences, Inc. Methods and uses of variant cd80 fusion proteins and related constructs
US11130802B2 (en) 2018-10-10 2021-09-28 Tilos Therapeutics, Inc. Anti-lap antibody variants
CN112867803A (en) 2018-10-16 2021-05-28 诺华股份有限公司 Tumor mutational burden alone or in combination with immune markers as biomarkers for predicting response to targeted therapy
CA3117016A1 (en) 2018-10-19 2020-04-23 Bristol-Myers Squibb Company Combination therapy for melanoma
US20220008515A1 (en) 2018-11-16 2022-01-13 Neoimmunetech, Inc. Method of treating a tumor with a combination of il-7 protein and an immune checkpoint inhibitor
EP3887397A1 (en) 2018-11-28 2021-10-06 Bristol-Myers Squibb Company Antibodies comprising modified heavy constant regions
CN113490499A (en) 2018-12-04 2021-10-08 大日本住友制药肿瘤公司 CDK9 inhibitors and polymorphs thereof as active agents for the treatment of cancer
CN109887035A (en) * 2018-12-27 2019-06-14 哈尔滨理工大学 Based on bat algorithm optimization BP neural network binocular vision calibration
JP2022518207A (en) 2019-01-17 2022-03-14 ジョージア テック リサーチ コーポレイション Drug delivery system containing oxidized cholesterol
JP2022520361A (en) 2019-02-12 2022-03-30 スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド Pharmaceuticals containing heterocyclic protein kinase inhibitors
AU2020222295B2 (en) 2019-02-12 2023-04-06 Novartis Ag Pharmaceutical combination comprising TNO155 and a PD-1 inhibitor
WO2020191326A1 (en) 2019-03-20 2020-09-24 Sumitomo Dainippon Pharma Oncology, Inc. Treatment of acute myeloid leukemia (aml) with venetoclax failure
AU2020245437A1 (en) 2019-03-22 2021-09-30 Sumitomo Pharma Oncology, Inc. Compositions comprising PKM2 modulators and methods of treatment using the same
EP3725370A1 (en) 2019-04-19 2020-10-21 ImmunoBrain Checkpoint, Inc. Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease
US20220233685A1 (en) 2019-06-18 2022-07-28 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and anti-pd-1 antibody
AU2020295012A1 (en) 2019-06-18 2022-02-17 Janssen Sciences Ireland Unlimited Company Combination of hepatitis B virus (HBV) vaccines and anti-PD-1 or anti-PD-L1 antibody
CA3145864A1 (en) 2019-07-03 2021-01-07 Sumitomo Dainippon Pharma Oncology, Inc. Tyrosine kinase non-receptor 1 (tnk1) inhibitors and uses thereof
WO2021024020A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
JP2022545741A (en) 2019-08-30 2022-10-28 アジェナス インコーポレイテッド ANTI-CD96 ANTIBODY AND METHODS OF USE THEREOF
TW202124446A (en) 2019-09-18 2021-07-01 瑞士商諾華公司 Combination therapies with entpd2 antibodies
CA3150265A1 (en) 2019-09-18 2021-03-25 Sara MAJOCCHI Bispecific antibodies against ceacam5 and cd3
US20220348651A1 (en) 2019-09-18 2022-11-03 Novartis Ag Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
JP2022548292A (en) 2019-09-19 2022-11-17 ブリストル－マイヤーズ スクイブ カンパニー Antibodies that bind VISTA at acidic pH
CN114786679A (en) 2019-10-21 2022-07-22 诺华股份有限公司 Combination therapy with Vernetork and TIM-3 inhibitors
TW202128191A (en) 2019-10-21 2021-08-01 瑞士商諾華公司 Tim-3 inhibitors and uses thereof
EP4051278A1 (en) 2019-10-29 2022-09-07 Eisai R&D Management Co., Ltd. Combination of a pd-1 antagonist, a vegfr/fgfr/ret tyrosine kinase inhibitor and a cbp/beta-catenin inhibitor for treating cancer
US20220395553A1 (en) 2019-11-14 2022-12-15 Cohbar, Inc. Cxcr4 antagonist peptides
WO2021102343A1 (en) 2019-11-22 2021-05-27 Sumitomo Dainippon Pharma Oncology, Inc. Solid dose pharmaceutical composition
WO2021108025A1 (en) 2019-11-26 2021-06-03 Massachusetts Institute Of Technology Cell-based cancer vaccines and cancer therapies
EP3831849A1 (en) 2019-12-02 2021-06-09 LamKap Bio beta AG Bispecific antibodies against ceacam5 and cd47
US11897950B2 (en) 2019-12-06 2024-02-13 Augusta University Research Institute, Inc. Osteopontin monoclonal antibodies
WO2021123902A1 (en) 2019-12-20 2021-06-24 Novartis Ag Combination of anti tim-3 antibody mbg453 and anti tgf-beta antibody nis793, with or without decitabine or the anti pd-1 antibody spartalizumab, for treating myelofibrosis and myelodysplastic syndrome
IL293752A (en) 2020-01-17 2022-08-01 Novartis Ag Combination comprising a tim-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemia
KR20220133996A (en) 2020-01-30 2022-10-05 오엔에이 테라퓨틱스 에스.엘. Combination therapy to treat cancer and cancer metastasis
AU2021225491A1 (en) 2020-02-28 2022-10-20 Novartis Ag A triple pharmaceutical combination comprising dabrafenib, an Erk inhibitor and a RAF inhibitor
CA3174442A1 (en) 2020-03-06 2021-09-10 ONA Therapeutics S.L. Anti-cd36 antibodies and their use to treat cancer
KR20220151189A (en) 2020-03-09 2022-11-14 브리스톨-마이어스 스큅 컴퍼니 Antibodies to CD40 with enhanced agonist activity
EP4132971A1 (en) 2020-04-09 2023-02-15 Merck Sharp & Dohme LLC Affinity matured anti-lap antibodies and uses thereof
EP4138819A1 (en) 2020-04-21 2023-03-01 Novartis AG Dosing regimen for treating a disease modulated by csf-1r
AU2021270750A1 (en) 2020-05-13 2022-12-08 Massachusetts Institute Of Technology Compositions of polymeric microdevices and their use in cancer immunotherapy
US20230192867A1 (en) 2020-05-15 2023-06-22 Bristol-Myers Squibb Company Antibodies to garp
US11767353B2 (en) 2020-06-05 2023-09-26 Theraly Fibrosis, Inc. Trail compositions with reduced immunogenicity
EP4178611A1 (en) 2020-07-07 2023-05-17 BioNTech SE Therapeutic rna for hpv-positive cancer
WO2022009157A1 (en) 2020-07-10 2022-01-13 Novartis Ag Lhc165 and spartalizumab combinations for treating solid tumors
JP2023537412A (en) 2020-08-13 2023-08-31 ブリストル－マイヤーズ スクイブ カンパニー Methods of Redirecting IL-2 to Target Cells of Interest
EP4204020A1 (en) 2020-08-31 2023-07-05 Advanced Accelerator Applications International S.A. Method of treating psma-expressing cancers
WO2022043557A1 (en) 2020-08-31 2022-03-03 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
EP4240491A1 (en) 2020-11-06 2023-09-13 Novartis AG Cd19 binding molecules and uses thereof
TW202237119A (en) 2020-12-10 2022-10-01 美商住友製藥腫瘤公司 Alk-5 inhibitors and uses thereof
US11753481B2 (en) 2020-12-18 2023-09-12 Lamkap Bio Beta Ltd Bispecific antibodies against CEACAM5 and CD47
TW202245808A (en) 2020-12-21 2022-12-01 德商拜恩迪克公司 Therapeutic rna for treating cancer
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
EP4284510A1 (en) 2021-01-29 2023-12-06 Novartis AG Dosage regimes for anti-cd73 and anti-entpd2 antibodies and uses thereof
TW202241508A (en) 2021-01-29 2022-11-01 美商艾歐凡斯生物治療公司 Cytokine associated tumor infiltrating lymphocytes compositions and methods
WO2022165403A1 (en) 2021-02-01 2022-08-04 Yale University Chemotherapeutic bioadhesive particles with immunostimulatory molecules for cancer treatment
TW202304506A (en) 2021-03-25 2023-02-01 日商安斯泰來製藥公司 Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
TW202304979A (en) 2021-04-07 2023-02-01 瑞士商諾華公司 USES OF ANTI-TGFβ ANTIBODIES AND OTHER THERAPEUTIC AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISEASES
TW202309022A (en) 2021-04-13 2023-03-01 美商努法倫特公司 Amino-substituted heterocycles for treating cancers with egfr mutations
TW202313117A (en) 2021-06-03 2023-04-01 美商欣爍克斯公司 Head and neck cancer combination therapy comprising an il-2 conjugate and cetuximab
AU2022312698A1 (en) 2021-07-13 2024-01-25 BioNTech SE Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
CA3226281A1 (en) 2021-07-30 2023-02-02 ONA Therapeutics S.L. Anti-cd36 antibodies and their use to treat cancer
WO2023051926A1 (en) 2021-09-30 2023-04-06 BioNTech SE Treatment involving non-immunogenic rna for antigen vaccination and pd-1 axis binding antagonists
CA3234647A1 (en) 2021-10-06 2023-04-13 Genmab A/S Multispecific binding agents against pd-l1 and cd137 in combination therapy
TW202333802A (en) 2021-10-11 2023-09-01 德商拜恩迪克公司 Therapeutic rna for lung cancer
WO2023077034A1 (en) 2021-10-28 2023-05-04 Lyell Immunopharma, Inc. Methods for culturing immune cells
WO2023083439A1 (en) 2021-11-09 2023-05-19 BioNTech SE Tlr7 agonist and combinations for cancer treatment
WO2023122573A1 (en) 2021-12-20 2023-06-29 Synthorx, Inc. Head and neck cancer combination therapy comprising an il-2 conjugate and pembrolizumab
WO2023147488A1 (en) 2022-01-28 2023-08-03 Iovance Biotherapeutics, Inc. Cytokine associated tumor infiltrating lymphocytes compositions and methods
WO2023170606A1 (en) 2022-03-08 2023-09-14 Alentis Therapeutics Ag Use of anti-claudin-1 antibodies to increase t cell availability
EP4249498A1 (en) * 2022-03-23 2023-09-27 Lipotrue, S.L. Peptides and compositions for use in cosmetics, food and medicine
WO2023192478A1 (en) 2022-04-01 2023-10-05 Bristol-Myers Squibb Company Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer
WO2023218046A1 (en) 2022-05-12 2023-11-16 Genmab A/S Binding agents capable of binding to cd27 in combination therapy
WO2023230554A1 (en) 2022-05-25 2023-11-30 Pfizer Inc. Combination of a braf inhibitor, an egfr inhibitor, and a pd-1 antagonist for the treatment of braf v600e-mutant, msi-h/dmmr colorectal cancer
WO2023242351A1 (en) 2022-06-16 2023-12-21 Lamkap Bio Beta Ag Combination therapy of bispecific antibodies against ceacam5 and cd47 and bispecific antibodies against ceacam5 and cd3
WO2024040264A1 (en) 2022-08-19 2024-02-22 Massachusetts Institute Of Technology Compositions and methods for targeting dendritic cell lectins
WO2024069009A1 (en) 2022-09-30 2024-04-04 Alentis Therapeutics Ag Treatment of drug-resistant hepatocellular carcinoma

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5618920A (en) * 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
AU6920194A (en) 1993-06-11 1995-01-03 Coulter Corporation Anti-cd3 antibody-aminodextran conjugates for induction of t-cell activation and proliferation
IL108501A (en) * 1994-01-31 1998-10-30 Mor Research Applic Ltd Antibodies and pharmaceutical compositions containing them
GB9416657D0 (en) 1994-08-17 1994-10-12 Biocine Spa T cell activation
GB9501079D0 (en) 1995-01-19 1995-03-08 Bioinvent Int Ab Activation of T-cells
IL129299A0 (en) 1999-03-31 2000-02-17 Mor Research Applic Ltd Monoclonal antibodies antigens and diagnosis of malignant diseases
IL145926A0 (en) * 2001-10-15 2002-07-25 Mor Research Applic Ltd Peptide epitopes of mimotopes useful in immunomodulation

Also Published As

Publication number Publication date
JP2006505244A (en) 2006-02-16
DK1575484T3 (en) 2015-10-12
AU2003230183A1 (en) 2003-12-12
ES2549303T3 (en) 2015-10-26
SI1575484T1 (en) 2015-11-30
US7524498B2 (en) 2009-04-28
KR101169254B1 (en) 2012-08-03
CA2487060C (en) 2011-01-04
PT1575484E (en) 2015-11-02
US20080025980A1 (en) 2008-01-31
WO2003099196A2 (en) 2003-12-04
IL207985A0 (en) 2010-12-30
IL165193A0 (en) 2005-12-18
KR20050008736A (en) 2005-01-21
JP2011139708A (en) 2011-07-21
US7981416B2 (en) 2011-07-19
HUE025710T2 (en) 2016-04-28
EP1575484A4 (en) 2006-11-22
IL207985A (en) 2013-10-31
US7332582B2 (en) 2008-02-19
IL149820A0 (en) 2002-11-10
US20090263386A1 (en) 2009-10-22
US20050180969A1 (en) 2005-08-18
EP1575484A2 (en) 2005-09-21
AU2003230183B2 (en) 2009-01-22
WO2003099196A3 (en) 2005-07-28
IL165193A (en) 2010-12-30
CY1117114T1 (en) 2017-04-05
JP4764627B2 (en) 2011-09-07
EP1575484B1 (en) 2015-07-08

Similar Documents

Publication Publication Date Title
CA2487060A1 (en) Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
US11136413B2 (en) PDL-1 antibody, pharmaceutical composition thereof, and uses thereof
KR102340832B1 (en) Anti-PD-1 antibodies and uses thereof
CN110799539B (en) Anti-4-1 BB antibodies and methods of making and using the same
CN112794909B (en) anti-TIGIT monoclonal antibody and application thereof
CN110291109A (en) The monoclonal antibody and its segment of people's programmed death receptor PD-1
JP2014518640A (en) Human antigen binding protein that binds to complex comprising β-croto and FGF receptor
JP2006505244A5 (en)
US10759859B2 (en) Anti-PD-1 antibodies and uses thereof
CN115991778A (en) anti-PD-L1 antibodies and uses thereof
CN114728065A (en) Antibodies to CD3 and BCMA and bispecific binding proteins prepared therefrom
JP2019514871A (en) Methods of administration of bispecific constructs that bind CD33 and CD3 for use in a method of treating myeloid leukemia
Akbari et al. Design, expression and evaluation of a novel humanized single chain antibody against epidermal growth factor receptor (EGFR)
WO2023186000A1 (en) Bispecific antibody and application thereof
CN113150156B (en) anti-TIGIT antibodies and uses thereof
CN115925917A (en) anti-PVRIG protein antibodies or antibody fragments and uses thereof
WO2022068854A1 (en) Antibodies targeting human claudin 18.2 and uses thereof
WO2023093744A1 (en) Bispecific antigen binding protein
WO2024077777A1 (en) Multifunctional recombinant antibody, and preparation method and use therefor
US20210079087A1 (en) Treatment of autoimmune and inflammatory disorders using antibodies that bind interleukin-17a (il-17a)
WO2018126595A1 (en) Antibody or antibody fragment capable of binding to lung-specific x protein and use thereof
TW202246340A (en) Anti-CTLA-4 antibody and use thereof
CN116848144A (en) anti-PD-L1 antibodies and uses thereof
KR20240049331A (en) Antibodies to human CD16a and variants thereof
CN117024592A (en) anti-B7H 3 antibodies and uses thereof

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20200831